September 16, 2020 The operational goal is to provide experienced oversight while advancing the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network toward long-term, local self-sustainability - to conduct high-quality research with a focus on emergent and high-impact public health research priorities in Liberia.
August 4, 2020 FHI Clinical is pleased to announce our partnership with Tiziana Life Sciences to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb), for the treatment of COVID-19 (SARS-CoV-2) patients.
July 23, 2020 Claudia Christian of FHI Clinical recently spoke with the editor for Outsourcing-Pharma about the clinical services that FHI Clinical is providing to the Frederick National Laboratory for Cancer Research for the ongoing ACTT adaptive study allowing investigation of putative therapeutics for the treatment of COVID-19 in hospitalized adults.
July 14, 2020 FHI Clinical Inc. announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT). ACTT is an adaptive study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults.
June 25, 2020 Several months ago, FHI Clinical began recruiting scientific and technological experts to join our newly formed panel of Scientific Advisory Experts, which was created to promote best practices, build alliances and spur innovation in the clinical trials research field. Today, we are pleased to announce that we have appointed five new members.
June 12, 2020 Claudia Christian, Senior VP, Clinical Operations, recently spoke with Seth Gulledge, writer for the Research Triangle Park, North Carolina-based Triangle Business Journal, about how the COVID-19 pandemic has disrupted the traditional model for clinical trials. This has prompted CROs around the Triangle to rapidly integrate virtual trial models to speed up clinical research and push COVID-19 vaccines and therapies to market.
June 8, 2020 Today, we commit to being better and doing more. We will continue consulting and partnering with the communities where we work, and we will redouble our efforts to ensure that their voices inform and shape the way we do our work. We will reexamine our internal structures and evolve our practices to root out imbalances and inequality and ensure that everyone is represented, included and empowered.
May 22, 2020 Preliminary results of the Adaptive COVID-19 Treatment Trial (ACTT) investigating remdesivir for the treatment of COVID-19 in hospitalized adults with evidence of lower respiratory tract involvement has been published in the New England Journal of Medicine . Of the FHI Clinical study team members, Danielle Fisher, Clinical Research Project Manager, and Wendi McDonald, Associate Project Manager, are listed on the manuscript for her contributions to the study.
April 16, 2020 Our president and CEO, Ted FitzGerald, talks with Outsourcing-Pharma about our partnership with IDRI on an immunotherapy clinical trial to combat COVID-19.
April 3, 2020 FHI Clinical Inc. announces today it has partnered with Infectious Disease Research Institute (IDRI), a Seattle-based not-for-profit organization, to provide full-service contract research organization (CRO) capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA